<unk> s are a novel type of antiandrogen that bind to the N-terminal<unk>  of the androgen receptor (AR) instead of the ligand-binding<unk>  (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.
N-Terminal domain antiandrogen
Antiandrogen
Selective androgen receptor modulator
Aromatase inhibitor
Steroidal antiandrogen
Steroidal aromatase inhibitor
Selective progesterone receptor modulator
Selective estrogen receptor modulator